from Reuters: U.S. https://ift.tt/2GlCpXR
Saturday, 24 March 2018
Home »
news
,
Reuters US
,
Reuters US news
,
Reuters: U.S.
» Trump moves to limit transgender individuals from military service
Trump moves to limit transgender individuals from military service
WASHINGTON (Reuters) - President Donald Trump signed a memorandum on Friday that bans some transgender individuals from serving in the U.S. military, but gives the armed forces latitude in implementing policies.

from Reuters: U.S. https://ift.tt/2GlCpXR
from Reuters: U.S. https://ift.tt/2GlCpXR
Related Posts:
First lady Melania Trump departs on four-country trip to AfricaU.S. first lady Melania Trump departed for Africa on Monday for a four-country trip that serves as her first major solo sojourn abroad on behalf of her husband President Donald Trump's administration. from Reuters: World… Read More
Magnitude 6.2 quake hits near Flores in Indonesia - USGSAn earthquake with a preliminary magnitude of 6.2 was recorded near the southern Indonesian island of Flores, the U.S. Geological Survey said on Tuesday, four days after a devastating quake on Sulawesi island killed at least … Read More
Scientists behind game-changing cancer immunotherapies win Nobel medicine prizeAmerican James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game-changing discoveries about how to harness and manipulate the immune system to fight cancer. from Reu… Read More
Brazil's far-right candidate Bolsonaro increases election lead: pollBrazil's far-right presidential candidate Jair Bolsonaro has a 10-point lead over leftist Workers Party candidate Fernando Haddad, and would tie in a second-round runoff against him next month, an opinion poll showed on Monda… Read More
Ono Pharma shares soar; Nobel awarded for cancer-fighting method used in its drugShares of Ono Pharmaceutical Co jumped to levels not seen in over two years after a Nobel Prize was awarded to researchers for a cancer-fighting method used in Opdivo, a drug it co-developed with Bristol-Myers Squibb Co . … Read More
0 comments:
Post a Comment